Research graph
References from The ALP score: a novel composite index for prognostic risk stratification to chemo-immunotherapy in advanced non-small cell lung cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Cancer statistics, 2025
10.3322/caac.21871 · 2025 · External reference
Non-small-cell lung cancer
10.1038/s41572-024-00551-9 · 2024 · External reference
Neoadjuvant chemoimmunotherapy for NSCLC: A systematic review and meta-analysis
10.1001/jamaoncol.2024.0057 · 2024 · External reference
Immune checkpoint inhibitor without pemetrexed for first-line maintenance therapy in advanced lung adenocarcinoma: A real-world retrospective study
10.1016/j.cllc.2025.08.011 · 2025 · External reference
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
10.1056/nejmoa1810865 · 2018 · External reference
Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC
10.1056/nejmoa1716948 · 2018 · External reference
IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC
10.1016/j.jtho.2021.07.009 · 2021 · External reference
Tumor immune microenvironment score predicts efficacy of immune checkpoint inhibitors-based regimens in advanced non-small cell lung cancer
10.1186/s12967-025-07408-z · 2025 · External reference
Immunotherapy change overcomes acquired resistance after chemo-immunotherapy in unresectable biliary tract cancer
10.1007/s00262-025-04181-2 · 2025 · External reference
Primary and acquired resistance against immune check inhibitors in non-small cell lung cancer
10.3390/cancers14143294 · 2022 · External reference
Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
10.3389/fimmu.2023.1127071 · 2023 · External reference
Treatment of NSCLC after chemoimmunotherapy - are we making headway
10.1038/s41571-025-01061-7 · 2025 · External reference
Addressing CPI resistance in NSCLC: Targeting TAM receptors to modulate the tumor microenvironment and future prospects
10.1136/jitc-2022-004863 · 2022 · External reference
Circulating low density neutrophils are associated with resistance to first line anti-PD1/PDL1 immunotherapy in non-small cell lung cancer
10.3390/cancers14163846 · 2022 · External reference
Peripheral lymphocyte count as a prognostic marker in cervical cancer patients treated with immune checkpoint inhibitors: A retrospective study
10.1186/s12885-025-15173-x · 2025 · External reference
Cytotoxic T lymphocyte density and PD-L1 expression predict the response to anti-PD1 therapy in recurrent oral squamous cell carcinoma
10.1111/1348-0421.13220 · 2025 · External reference
Low geriatric nutritional risk index as a poor prognostic biomarker for immune checkpoint inhibitor treatment in solid cancer
10.3389/fnut.2023.1286583 · 2023 · External reference
Predictive value of the lung immune prognostic index for immune checkpoint inhibitor therapy outcomes in non-small cell lung cancer: A systematic review and meta-analysis
10.18502/ijaai.v24i2.18141 · 2025 · External reference
Mutational landscape of recurrent/metastatic head and neck squamous cell carcinoma and association with immune checkpoint inhibitor outcomes
10.1158/1078-0432.ccr-24-2198 · 2025 · External reference
Peripheral lymphocyte count as a surrogate marker of immune checkpoint inhibitor therapy outcomes in patients with non-small-cell lung cancer
10.1038/s41598-021-04630-9 · 2022 · External reference
Real-world outcomes of 18,186 metastatic solid tumor outpatients: Baseline blood cell counts correlate with survival after immune checkpoint inhibitor therapy
10.1002/cam4.6645 · 2023 · External reference
Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer
10.1002/eji.202048966 · 2021 · External reference
Serum albumin: Early prognostic marker of benefit for immune checkpoint inhibitor monotherapy but not chemoimmunotherapy
10.1016/j.cllc.2021.12.010 · 2022 · External reference
Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer
10.1016/j.esmoop.2021.100254 · 2021 · External reference
